TU Dresden


Next step towards the prevention of blindness: CRTD researchers obtain an U.S.-patent for a method to highly efficiently produce human retinal pigment epithelium cells (RPE)


The research team around Prof. Elly Tanaka at the DFG Research Center for Regenerative Therapies Dresden (CRTD) - Cluster of Excellence at the TU Dresden succeeded in the development of a method to produce highly efficiently functional retinal pigment epithelium cells (RPE) that are crucially influencing the sense of sight. Being already under patent protection in the European Union, the method is also under protection in the U.S. since February 2016 (US9249390 B2, 02.02.2016). The produced cells can be used for cell replacement therapies for hitherto incurable eye diseases as well as pharmacological screens.